When can soreness wait, and when can’t it?

When is a regular joint visit reasonable?

Plan a regular visit if soreness keeps returning or cuts into your usual day. The doctor will ask how it began and which movements hurt. Take records from earlier care and write down every medicine you use. Expect questions about sleep, walking, work, and hobbies.

A QC Kinetix consultation may cover regenerative treatments, office procedures where a doctor or another licensed medical provider examines the joint and may use spun marrow, washed fat, or platelets separated from your blood. Ask why the offered procedure fits what the exam found. I’d also ask what simpler care remains worth trying. The reason can’t be the same for every joint.

What health concerns may change the visit?

Tell the clinic about recent illness, infection, bleeding trouble, or active cancer treatment. Blood thinners need careful review before marrow is drawn. Don’t stop one on your own. The doctor who prescribed it needs to agree with any change.

Mention allergies and any bad reaction during an earlier procedure. Ask what to do if you become sick before the appointment. A delay may be safer than going ahead. Your health matters more than keeping a date.

Which warning signs need faster care?

A joint that is hot and swollen with fever needs quick medical care. Get prompt care if an injury suddenly stops you from standing. An oddly shaped joint, numbness that just began, or a sudden loss of strength also needs attention. Those symptoms can’t wait for a regular treatment visit.

Calf soreness with swelling or redness after a procedure may mean a blood clot. Fever, wound drainage, or spreading redness may mean infection. Call promptly instead of waiting for follow-up. If the symptoms are severe, urgent care may be the right place.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.

3. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

4. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

5. On 27 September 2024 the Ninth Circuit held in United States v. California Stem Cell Treatment Center that stromal vascular fraction produced by enzymatically digesting a patient's own fat IS a drug under the Federal Food, Drug, and Cosmetic Act, and that the same surgical procedure exception does not apply because the removed fat and the implanted SVF are not the same thing. The district court's ruling for the clinics was reversed.

   United States Court of Appeals for the Ninth Circuit — United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024). , 2024.